Patients with malignant mesothelioma harboring NF2 mutations respond to TEAD inhibitor [56]; however, the NF2 mutation rate in lung squamous cell carcinoma is only 2.2% [57]. The gene discussed is NF2; the disease is squamous cell lung carcinoma.